1. Search Result
Search Result
Results for "

autoradiography

" in MedChemExpress (MCE) Product Catalog:

7

Inhibitors & Agonists

1

Peptides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-100619
    BMS-986020
    5+ Cited Publications

    AM152

    LPL Receptor Metabolic Disease Inflammation/Immunology
    BMS-986020 (AM152) is a high-affinity and selective lysophosphatidic acid receptor 1 (LPA1) antagonist . BMS-986020 inhibits bile acid and phospholipid transporters with IC50s of 4.8 μM, 6.2 μM, and 7.5 μM for BSEP, MRP4, and MDR3, respectively . BMS-986020 has the potential for the treatment of idiopathic pulmonary fibrosis (IPF) .
    BMS-986020
  • HY-100619A
    BMS-986020 sodium
    5+ Cited Publications

    AM152 sodium

    LPL Receptor Metabolic Disease Inflammation/Immunology
    BMS-986020 (AM152) sodium is a high-affinity lysophosphatidic acid receptor 1 (LPA1) antagonist . BMS-986020 sodium inhibits bile acid and phospholipid transporters with IC50s of 4.8 μM, 6.2 μM, and 7.5 μM for BSEP, MRP4, and MDR3, respectively . BMS-986020 sodium has the potential for the treatment of idiopathic pulmonary fibrosis (IPF) .
    BMS-986020 sodium
  • HY-179492

    hnRNP Neurological Disease
    ACI-19278 is a TDP-43 PET tracer with an average Kd of 25 nM. ACI-19278 only binds to pathological TDP-43 aggregates and does not cross-react with Aβ, Tau, etc. [ 18F]ACI-19278 successfully visualized the TDP-43 pathology in the human brain through positron emission computed tomography. ACI-19278 can be used for in vivo diagnosis of TDP-43 protein lesions .
    ACI-19278
  • HY-12761

    Cannabinoid Receptor Cardiovascular Disease Others Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    A-836339 is a selective CB2 receptor agonist, with Ki values of 0.4 nM and 0.8 nM in humans and rats, respectively. A-836339 exhibits multiple effects such as analgesia, gastric protection, anti-inflammation, and antioxidant activity. A-836339 produces antinociceptive and analgesic activities by activating CB2 receptors in the dorsal root ganglia and spinal cord. A-836339 can also exert gastric protective effects through anti-inflammatory mechanisms (reducing TNF-α and IL-1β) and antioxidant mechanisms (enhancing the activities of CAT and SOD, and reducing H2O2). Radioactively labeled A-836339 can serve as a CB2-specific radioligand for autoradiography and PET imaging. A-836339 can be used in research on inflammatory pain, neuropathic pain, gastric ulcers, cerebral ischemia, etc .
    A-836339
  • HY-P11263

    iGluR Neurological Disease
    AVLX-144 is a highly potent inhibitor of postsynaptic density protein 95 (PSD-95). AVLX-144 can be used as a template to develop imaging probes for postsynaptic density (PSD) molecules, and can be labeled with fluorine-18 (¹⁸F) or tritium (³H) to visualize PSD-95 in vivo. AVLX-144 can be utilized for the study of Parkinson's disease .
    AVLX-144
  • HY-100619AR

    AM152 sodium (Standard)

    LPL Receptor Reference Standards Metabolic Disease Inflammation/Immunology
    BMS-986020 (sodium) (Standard) is the analytical standard of BMS-986020 (sodium) (HY-100619A). This product is intended for research and analytical applications. BMS-986020 (AM152) sodium is a high-affinity lysophosphatidic acid receptor 1 (LPA1) antagonist . BMS-986020 sodium inhibits bile acid and phospholipid transporters with IC50s of 4.8 μM, 6.2 μM, and 7.5 μM for BSEP, MRP4, and MDR3, respectively . BMS-986020 sodium has the potential for the treatment of idiopathic pulmonary fibrosis (IPF) .
    BMS-986020 sodium (Standard)
  • HY-100619R

    AM152 (Standard)

    LPL Receptor Reference Standards Metabolic Disease Inflammation/Immunology
    BMS-986020 (Standard) is the analytical standard of BMS-986020 (HY-100619). This product is intended for research and analytical applications. BMS-986020 (AM152) is a high-affinity and selective lysophosphatidic acid receptor 1 (LPA1) antagonist . BMS-986020 inhibits bile acid and phospholipid transporters with IC50s of 4.8 μM, 6.2 μM, and 7.5 μM for BSEP, MRP4, and MDR3, respectively . BMS-986020 has the potential for the treatment of idiopathic pulmonary fibrosis (IPF) .
    BMS-986020 (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: